DOCKET NO.: KLI-0002 PATENT APPLICATION

SERIAL NO.: 09/801,470

FILED: MARCH 8, 2001

Summary of the Amendment

Claims 25-36 and 54-63 have been canceled as being directed to non-elected inventions.

Claim 1 has been amended to remove reference to woman being suspected of being infertile from the preamble. No new matter has been added.

New claims 64 is dependent on claim 1 and recites the limitation that the woman is suspected of being infertile. Support for new claim 64 is found throughout the specification and claims as filed. No new matter has been added.

New claims 65-79 are dependent on new claim 64 and correspond to claims 2-16, respectively. Support for new claims 65-79 is found throughout the specification and claims as filed. No new matter has been added.

New claims 80-82 are dependent on claims 64, 1 and 17 and recite the limitation that the woman being tested for abnormal endometrial development is undergoing a hormone replacement mock trial. Support for new claims 80-82 is found throughout the specification and claims as filed. No new matter has been added.

Conclusion

Claims 1-24, 37-54 and 64082 are in condition for allowance. A Notice of Allowance is earnestly solicited.

DOCKET NO.: KLI-0002 PATENT APPLICATION

SERIAL NO.: 09/801,470 FILED: MARCH 8, 2001

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with markings to show changes made."

Respectfully submitted,

Mark DeLuca

Registration No. 33,229

Date: 8/7

WOODCOCK WASHBURN LLP One Liberty Place - 46th Floor Philadelphia, PA 19103 (215) 568-3100 DOCKET NO.: KLI-0002 PATENT APPLICATION

SERIAL NO.: 09/801,470 FILED: MARCH 8, 2001

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

Claims 25-36 and 54-63 have been canceled.

New claims 64-82 have been added.

Claim 1 has been amended as follows.

1 (Amended). A method of diagnosing an abnormality in endometrial glandular development in a woman [suspected of being infertile] comprising the step of:

detecting expression of cyclin E in the nuclei and/or the cytoplasm of endometrial gland cells in an endometrial tissue sample from on or after day 20 of an idealized 28 day menstrual cycle from a woman suspected of being infertile;

wherein

expression of cyclin E in the nuclei of greater than 5% of the gland cells indicates endometrial glandular developmental arrest, and/or

expression of cyclin E of greater than 1+ staining intensity in the cytoplasm of greater than 10% of the gland cells indicates endometrial glandular developmental arrest.